RT Journal Article SR Electronic T1 Nationwide, large-scale implementation of an online system for remote entry of patient-reported outcomes in rheumatology: characteristics of users and non-users and time to first entry JF RMD Open JO RMD Open FD EULAR SP e002549 DO 10.1136/rmdopen-2022-002549 VO 8 IS 2 A1 Bente Glintborg A1 Dorte Vendelbo Jensen A1 Lene Terslev A1 Oliver Hendricks A1 Mikkel Østergaard A1 Simon Horskjær Rasmussen A1 Mogens Pfeiffer Jensen A1 Thomas Adelsten A1 Ada Colic A1 Kamilla Danebod A1 Malene Kildemand A1 Anne Gitte Loft A1 Heidi Lausten Munk A1 Jens Kristian Pedersen A1 René Drage Østgård A1 Christian Møller Sørensen A1 Niels Steen Krogh A1 Jette Agerbo A1 Connie Ziegler A1 Merete Lund Hetland YR 2022 UL http://rmdopen.bmj.com/content/8/2/e002549.abstract AB Aims In May 2020, a nationwide, web-based system for remote entry of patient-reported outcomes (PROs) in inflammatory rheumatic diseases was launched and implemented in routine care (DANBIO-from-home). After 1.5 years of use, we explored clinical characteristics of patients who did versus did not use the system, and the time to first entry of PROs.Methods All patients followed in DANBIO were informed about DANBIO-from-home by electronic invitations or when attending their clinic. Characteristics of patients who did/did not use DANBIO-from-home in the period after implementation were explored by multivariable logistic regression analyses including demographic and clinical variables (gender, age group, diagnosis, disease duration, use of biological disease-modifying agent (bDMARD), Health Assessment Questionnaire (HAQ), Patient Acceptable Symptom Scale (PASS)). Time from launch to first entry was presented as cumulative incidence curves by age group (<40/40–60/61–80/>80 years).Results Of 33 776 patients, 68% entered PROs using DANBIO-from-home at least once. Median (IQR) time to first entry was 27 (11–152) days. Factors associated with data entry in multivariate analyses (OR (95% CI)) were: female gender (1.19 (1.12 to 1.27)), bDMARD treatment (1.41 (1.33 to 1.50)), age 40–60 years (1.79 (1.63 to 1.97)), 61–80 years (1.87 (1.70 to 2.07), or age >80 years (0.57 (0.50 to 0.65)) (reference: age <40 years), lower HAQ (0.68 (0.65 to 0.71)) and PASS ‘no’ (1.09 (1.02 to 1.17). Diagnosis was not associated. Time to first entry of PROs was longest in patients <40 years of age (119 (24–184) days) and shortest in the 61–80 years age group (25 (8–139) days).Conclusion A nationwide online platform for PRO in rheumatology achieved widespread use. Higher age, male gender, conventional treatment and disability were associated with no use.All data relevant to the study are included in the article or uploaded as supplemental information. Data are available upon reasonable request.